- Achieving serum urate below 6 mg/dL within 12 months of starting urate-lowering therapy was associated with a lower 5-year risk of major adverse cardiovascular events.
- Relative cardiovascular risk reduction with target attainment was 9% compared with non-achievement.
- Greater risk reduction was observed among patients at high baseline cardiovascular risk.
- Achieving a stricter serum urate level below 5 mg/dL was linked to larger cardiovascular risk decreases.
- Patients who reached urate targets also had fewer gout flares during follow-up.
Source: JAMA Internal Medicine
